• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

168.33 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 470
Open 168.33
Bid (Size) 166.24 (200)
Ask (Size) 167.97 (100)
Prev. Close 168.33
Today's Range 168.33 - 168.33
52wk Range 61.06 - 191.05
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
October 05, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Cash-Burning Stocks with Questionable Fundamentals
October 05, 2026
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy Supply Chain

Performance

52-Week Range 11.9% below 52-week high
168.33
61.0652W Low 191.0552W High
1 Week 11.9% below 1-week high
165.001W Low 191.051W High

Guardant Health, Inc. - Common Stock (GH) traded between $61.06 and $191.05 over the past 52 weeks and last traded at $168.33, 11.9% below its 52-week high. Over the past week it ranged between $165.00 and $191.05.

Past 12 Months
-3.7%
+4.6%
+7.8%
+81.3%
+65.5%
+165.3%
1W -$6.42
1M +$7.35
3M +$12.16
6M +$75.49
YTD +$66.59
1Y +$104.89

GH was +165.3% over the past year, +81.3% over six months, +65.5% year to date, -3.7% in the last week.

12 Months vs Market
GH
+165.3%
DIA
+9.7%
SPY
+16.2%
QQQ
+25.3%
IWM
+13.7%

Over the past 12 months GH returned +165.3% versus DIA (Dow) +9.7%, SPY (S&P 500) +16.2%, QQQ (Nasdaq 100) +25.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.00× 3-mo avg
Today 470 3-mo avg 2.0M
1W
2.2M
1M
1.9M
3M
2.0M
6M
2.4M
YTD
2.2M
1Y
2.3M

GH most recently traded 470 shares against a 3-month average daily volume of 2.0M.

More News

Read More
News headline image
1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore
September 29, 2026
Via StockStory
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Question
September 21, 2026
Via StockStory
Topics Credit Cards
Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook ↗
July 30, 2026
Via Chartmill
News headline image
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
September 15, 2026
Via StockStory
News headline image
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
September 14, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
September 09, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Business Insider Names Guardant Health One of America's Most Innovative Businesses
September 08, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
1 Growth Stock to Add to Your Roster and 2 We Turn Down
September 08, 2026
Via StockStory
News headline image
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
September 04, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
September 01, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Rule Breakers Buy a Stock That's Already "Won" ↗
August 31, 2026
Via The Motley Fool
Topics Death
News headline image
Guardant Health to Appeal Federal District Court Judgment
August 24, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate ↗
August 14, 2026
Via MarketBeat
News headline image
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million ↗
August 12, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health (GH) Q2 2026 Earnings Call Transcript ↗
August 07, 2026
Via The Motley Fool
Topics Earnings
News headline image
2 Cash-Burning Stocks to Target This Week and 1 We Find Risky
August 03, 2026
Via StockStory
Topics Energy
News headline image
GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth
August 01, 2026
Via StockStory
News headline image
Guardant Health Q2 Earnings Call Highlights ↗
July 31, 2026
Via MarketBeat
Topics Earnings
News headline image
Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars
July 30, 2026
Via StockStory
News headline image
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
July 30, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
July 29, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health (GH) Q2 Earnings Report Preview: What To Look For
July 28, 2026
Via StockStory

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?
Yes, Guardant Health, Inc. - Common Stock is publicly traded.
What exchange does Guardant Health, Inc. - Common Stock trade on?
Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Guardant Health, Inc. - Common Stock?
The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market
What is the current price of Guardant Health, Inc. - Common Stock?
The current price of Guardant Health, Inc. - Common Stock is 168.33
When was Guardant Health, Inc. - Common Stock last traded?
The last trade of Guardant Health, Inc. - Common Stock was at 10/07/26 04:00 PM ET
What is the market capitalization of Guardant Health, Inc. - Common Stock?
The market capitalization of Guardant Health, Inc. - Common Stock is 17.05B
How many shares of Guardant Health, Inc. - Common Stock are outstanding?
Guardant Health, Inc. - Common Stock has 17B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap